SEC Filing Summary: Hemispherx Biopharma, Inc.
Business Context and Reporting Period
This Form 8-K reports on the results of the 2014 Annual Meeting of Stockholders held on November 12, 2014. The filing was submitted on November 14, 2014. A quorum of 40.0% was present at the meeting.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders voted on three primary matters:
- Election of Directors: All five nominees were elected. William A. Carter and Thomas K. Equels received significant support (approx. 17.4M and 17.6M votes for, respectively). William M. Mitchell, Iraj E. Kiani, and Peter W. Rodino, III received fewer votes for (approx. 11.6M each) with higher withheld votes (approx. 8.1M each), though all were elected.
- Ratification of Independent Accountants: McGladrey LLP was ratified with 94,658,559 votes for, 6,246,533 against, and 890,619 abstentions.
- Executive Compensation Advisory Vote: The non-binding resolution was defeated. Votes were 8,754,513 for, 10,119,874 against, and 807,219 abstentions. There were 82,114,105 broker non-votes.
Guidance, Outlook, and Risks
The filing text does not provide specific guidance, outlook, management commentary, or risk factors. It references a press release dated November 14, 2014 (Exhibit 99.1) for further information.
Key Facts for Investor Verification
- Verify the implications of the failed advisory vote on executive compensation.
- Review the November 14, 2014 press release (Exhibit 99.1) for management's response to the voting results.
- Confirm the final composition of the Board of Directors following the election.